Avacopan Dosing for ANCA-Associated Vasculitis
The recommended dose of avacopan for ANCA-associated vasculitis is 30 mg orally twice daily, used during induction therapy in combination with rituximab or cyclophosphamide, and continued for 52 weeks. 1, 2
Dosing Regimen
Induction and Maintenance
- Dose: 30 mg twice daily (total 60 mg/day)
- Duration: 52 weeks
- Route: Oral administration
- Food considerations: Should be taken with food (increases AUC by 72% but this is the studied condition) 2
Role in Treatment Algorithm
Avacopan serves as an alternative to glucocorticoids, not as monotherapy 1. It must be combined with standard immunosuppressive therapy:
- Rituximab (375 mg/m² weekly × 4 weeks), OR
- Cyclophosphamide (IV: 15 mg/kg at weeks 0,2,4,7,10,13; Oral: 2 mg/kg/day for 3 months)
Clinical Context and Patient Selection
Prioritize avacopan for patients who:
- Have increased risk of glucocorticoid toxicity (diabetes, osteoporosis, obesity, psychiatric history)
- Present with lower GFR (greater potential for renal recovery) 1
- Have active glomerulonephritis with rapidly declining kidney function 3
The 2024 KDIGO guidelines explicitly state avacopan is used "as alternative to glucocorticoids" during induction, allowing substantial reduction in steroid exposure 1.
Evidence Base
The ADVOCATE trial (N=331) established this dosing regimen, demonstrating:
- Week 26 remission: 72.3% with avacopan vs 70.1% with prednisone (noninferior)
- Week 52 sustained remission: 65.7% with avacopan vs 54.9% with prednisone (superior, p=0.007)
- Glucocorticoid reduction: 2.3 g less cumulative steroid exposure over 52 weeks
- Renal recovery: Greater eGFR improvement in patients with baseline glomerulonephritis 2, 4
In the rituximab subgroup specifically (64.8% of ADVOCATE patients), avacopan showed sustained remission rates of 71.0% vs 56.1% with prednisone at week 52 5.
Dosing Modifications
No dose adjustments required for:
- Renal impairment (mild, moderate, or severe) 2
- Hepatic impairment (Child-Pugh A or B) 2
- Age (studied in patients 18-83 years) 2
- Body weight 2
Not studied in:
- Severe hepatic impairment (Child-Pugh C)
- Patients on dialysis at baseline 2
Duration Beyond 52 Weeks
The FDA approval and clinical trial data support 52 weeks of treatment 2. Limited real-world data suggest some patients receive longer courses with sustained eGFR improvement and acceptable safety profiles, though infections remain the primary concern 6. The 2024 KDIGO guidelines note "there are no data on use of avacopan beyond 1 year, so longer-term use cannot be recommended" 3.
Critical Caveats
Drug interactions: Avacopan is metabolized by CYP3A4. Strong CYP3A4 inhibitors (itraconazole) increase avacopan exposure by 87% for Cmax and 2.5-fold for AUC. Conversely, avacopan increases simvastatin exposure 3.5-fold 2. Monitor and adjust interacting medications accordingly.
Safety monitoring: Serious adverse events occurred in 37.3% of avacopan-treated patients (similar to 39.0% with prednisone). Infections requiring hospitalization are the most common serious complication 2, 4, 6.
Not a glucocorticoid replacement in all scenarios: Patients still require glucocorticoids for rituximab premedication, treatment of persistent/worsening vasculitis, relapses, and non-vasculitis indications like adrenal insufficiency 2.